[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"rhinovirus-infection\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:rhinovirus-infection":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,42,72,105],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100640888","phase-2-trial-comparing-the-safety-and-efficacy-of-two-different-oral-vpv-doses-with-placebo-as-treatment-for-rv-in-participants-with-copd-100640888",false,"NCT07610395","Trial Comparing the Safety and Efficacy of Two Different Oral VPV Doses With Placebo as Treatment for RV in Participants With COPD","A Multi-center, Randomized, Double-blind, Placebo-controlled Clinical Trial Comparing the Safety and Efficacy of Two Different Oral Vapendavir (VPV) Doses With Placebo as Treatment for Rhinovirus (RV) in Participants With Chronic Obstructive Pulmonary Disease (COPD)","Cardinal COPD","Inclusion\n\nSign informed consent for study participation and medical records release (if needed).\n\nMale or female age ≥40 years and ≤85 years at the time of signing the informed consent at Screening.\n\nIf sexually active and\u002For of child-bearing potential (both females and males), must agree to use a highly effective form of contraception at the time of randomization until 30 days (females) or 90 days (males) after the last dose. Female participants may not use hormonal birth control as a sole method. Participants will be asked to commit to this criterion at screening even though it does not need to be implemented until treatment is received. See Section 11.2 below.\n\nConfirmed diagnosis of COPD, defined as chronic cough, sputum production, and\u002For dyspnea with airflow obstruction which is not fully reversible (that is, post bronchodilator FEV1\u002FFVC ratio \\\u003C0.70 and post bronchodilator FEV1 ≥20% and \\\u003C80% of predicted normal value).\n\nHistory of AECOPD with at least 1 documented AECOPD within 1 year of Screening.\n\n* AECOPD is defined as an event characterized by dyspnea and\u002For cough and increased sputum purulence\u002Fchange in sputum color that worsens over several days, and requires at least one of the following for at least 2 days:\n* Increase frequency or dose of beta agonist(s), oxygen, breathing treatments or chronic COPD medications (Mild Exacerbation)\n* Use of oral or systemic steroids (Moderate Exacerbation), or\n* Use of Antibiotics (Moderate Exacerbation), or\n* Emergency room visit or hospitalization (Severe Exacerbation). CAT score ≥10 at screening. Able to comply with all study requirements, including the use of a mobile application to complete daily PROs, perform nasal swabs at home, and able to assess when they have cold symptoms.\n\nInteracts with people at least twice a week without a mask (e.g., grocery shopping, dinner with grandchildren, eating at a restaurant, going to the movies, etc.) or are living in a multigenerational home.\n\nInclusion criteria to be assessed only at Randomization:\n\nIf on stable COPD maintenance therapy this should be stable for at least 2 months prior to randomization. Changes allowed with Sponsor approval (i.e., change within same class due to financial considerations and clinically stable).\n\nClinically stable with no other exacerbations or respiratory infections (viral or bacterial) within 2 months prior to randomization.\n\nThe presence of RV (without a co-infection) at the time of randomization based on an approved molecular diagnostic test.\n\nTo be randomized, participants must have at least 3 E-RS scores completed within the previous 35 days to establish a PSB.\n\nExclusion\n\nPregnant or nursing or expected to become pregnant during the study period. Experiencing a current\u002Factive or prior exacerbation within 2 months of the Screening Visit (these participants should be rescreened after the exacerbation has been resolved for two months).\n\nParticipants with other primary causes of chronic airflow limitation:\n\n\\- Including but not limited to: asthma alone (COPD with asthmatic features is acceptable), CF, bronchiolitis obliterans, fibrosis such as TB, IPF, non-CF bronchiectasis with multi-lobe involvement or other major respiratory diagnosis (e.g., allergic bronchopulmonary aspergillosis), etc.\n\nAny disorder, for example, cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, hematological, psychiatric impairment that is not medically stable, or other major physical impairment that is not considered by the investigator medically stable\u002Fcontrolled.\n\nParticipants with hepatitis B are excluded. Participants on a stable treatment for HIV can be permitted with permission from the medical monitor. Participants with hepatitis C should be treated and confirmed HCV RNA negative prior to enrollment. (Testing performed at the Screening Visit).\n\nIn the Investigator's opinion, the participant has any clinically significant laboratory abnormality including an abnormality that indicates clinically significant hematologic, hepatobiliary, or renal disease.\n\nPresence of clinically significant out-of-range cardiac interval on the screening ECG including a QTcF \\> 450 msec (men) and a QTcF \\> 460 msec (women).\n\nMedications or other non-medicinal products that could be impacted by CYP3A4, CYP2C8, or CYP2C19 induction and have serious complications for the participant within the treatment period.\n\nMedications that are potent CYP2C8, CYP3A4 or CYP2C19 inducers that would reduce exposures of VPV.\n\nMedications that are potent CYP2C8, CYP3A4, or CYP2C19 inhibitors that would increase exposures of VPV.\n\nMedications that are substrates of MATE1, OAT3, P-gp, and BCRP for which elevated concentrations are associated with serious and\u002For life-threatening reactions.\n\nUse of either of the following treatments:\n\n* Chronic oral\u002Fsystemic steroids \\>10 mg per day (inhaled corticosteroids are permitted).\n* Continuous oxygen via nasal cannula of \\>2 L\u002Fmin at the time of Screening or during the Asymptomatic Phase. (Participants on continuous oxygen may have the rate increased during physical exercise\u002F exertion or to cover any situationally induced decompensation, so long as the participant will resume a continuous rate of ≤2 L\u002Fmin thereafter).\n\nParticipation in another investigational drug study within 5 half-lives prior to Screening and during the study is prohibited. This includes approved drugs being evaluated for a new indication. Observational studies are permitted.\n\nParticipants who have taken VPV in another clinical trial.\n\nExclusion criteria to be assessed only at Randomization:\n\nIt is already determined, based on the Investigator's clinical judgement, that the participant will likely need antibiotics and\u002For oral steroids at the Day 1 Randomization Visit.\n\nOn or within 7 days prior to randomization, there is another active diagnosed infection with viral or bacterial pathogens (i.e., urinary tract infection, cellulitis, etc.) that requires treatment.","ALL","40 Years","85 Years",{"count":21,"type":22},180,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","Compare the safety and efficacy of two different oral vapendavir doses with placebo in order to determine the appropriate dose of vapendavir to reduce the severity and\u002For duration of respiratory symptoms associated with RV infections in patients with COPD.",[28],"Rhinovirus Infection","RECRUITING","2026-06-22",{"date":32,"type":33},"2026-06-24","ACTUAL",{"date":35,"type":33},"2026-05-01",{"date":37,"type":22},"2027-11-15",{"name":39,"class":40},"Altesa Biosciences, Inc.","INDUSTRY",14,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":71},"100639061","virological-surveillance-of-acute-respiratory-infection-in-primary-health-care-in-metropolitan-france-100639061","NCT07599449","Virological Surveillance of Acute Respiratory Infection in Primary Health Care in Metropolitan France","RS-viro IRA","Inclusion Criteria:\n\n* be seen by a general practitioner or pediatrician participating in the Sentinelles surveillance program;\n* between week 40 (late September-early October) and week 15 (mid-April) of each year\n* have an acute respiratory infection (ARI) as defined below: Sudden onset of fever (or feeling of fever) and respiratory symptoms\n* have given oral consent to participate in this monitoring or, in the case of minors, oral consent given by the child's legal guardian(s) present at the consultation\n\nExclusion Criteria:\n\n* a person who is subject to a court-ordered protective measure;\n* a person who is under guardianship or conservatorship, unless accompanied by their legal guardian or unless the legal guardian objects to their participation;\n* a person who is not in a condition to receive information or give consent.",{"count":50,"type":22},25000,"OBSERVATIONAL","Every year in the fall and winter, numerous respiratory viruses (such as influenza viruses, SARS-CoV-2 (COVID-19), RSV, rhinovirus, and metapneumovirus) circulate in mainland France, causing acute respiratory infections (ARIs). These viruses can cause epidemics of varying severity, requiring close monitoring to determine their circulation levels and adapt public health measures accordingly. In France, ARI surveillance relies on two networks: the Sentinelles network in primary care and the RENAL network in hospitals. The Sentinelles surveillance is conducted in collaboration with Santé publique France, the National Reference Center for Respiratory Infection Viruses (Institut Pasteur and Hospices Civils de Lyon), and the University of Corsica. As part of the virological surveillance of ARIs, Sentinelles physicians are asked to collect nasopharyngeal swabs or saliva samples from a sample of patients presenting with an ARI during their clinic visits. This surveillance makes it possible to identify respiratory viruses circulating in primary care (general practice and pediatrics), to describe confirmed cases for each of the circulating viruses, and to estimate the impact of each on general practice. This surveillance also allows for the evaluation of the effectiveness of vaccines against influenza and COVID-19.",[54,55,56,57,58,28,59],"Respiratory Tract Infections (RTI)","Influenza -Like Illness","Influenza","COVID - 19","RSV Infections","Metapneumovirus Infection","NOT_YET_RECRUITING","2026-06-03",{"date":63,"type":33},"2026-06-05",{"date":65,"type":22},"2026-05-15",{"date":67,"type":22},"2031-05-20",{"name":69,"class":70},"Institut National de la Santé Et de la Recherche Médicale, France","OTHER_GOV",1,{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":80,"sex":17,"minAge":18,"maxAge":81,"enrollmentInfo":82,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":84,"conditions":85,"keywords":88,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":71},"100601572","using-multiomics-to-define-mechanisms-of-rhinovirus-induced-chronic-obstructive-pulmonary-disease-exacerbations-to-develop-novel-therapies-and-therapeutic-targets-100601572","NCT07112235","Using Multiomics to Define Mechanisms of Rhinovirus-induced Chronic Obstructive Pulmonary Disease Exacerbations to Develop Novel Therapies and Therapeutic Targets","Using Multiomics to Define Mechanisms of RhinoVirus-induced Chronic Obstructive Pulmonary Disease Exacerbations to Develop Novel Therapies and Therapeutic Targets","MRVCOPD","Inclusion Criteria for COPD subjects\n\n* Male or female sex\n* Age ≥40 years and ≤75 years at the time of signing the consent form\n* Medical history or clinical diagnosis of COPD\n* Significant smoking history, defined as:\n\n  * Cumulative smoking history of at least 20 pack years\n  * Permitted to currently use, or have history of use of, e-cigarettes\u002Fvapes\n* COPD spirometry criteria:\n\n  * Post bronchodilator FEV1 of \\\u003C80% and ≥50% predicted for age and height (equivalent to GOLD criteria stage 2 for 'Moderate' severity COPD9)\n  * Post-bronchodilator FEV1\u002FFVC ratio \\\u003C0.7\n  * β-agonist reversibility: an improvement of less than 12% predicted FEV1 and less than 200mL after 200 micrograms of salbutamol or equivalent short acting beta-2 agonist bronchodilator.\n* History of acute exacerbations of COPD as defined by the participant answering \"yes\" to the question: \"do your COPD symptoms get noticeably worse when you catch a cold?\"\n* Clinically stable with no COPD exacerbations within 8 weeks prior to enrolment\n* Permitted to take short and long-acting bronchodilators including beta agonists and muscarinic antagonist inhalers\n* Co-morbidity criteria:\n\n  * Permitted to have a past medical history of asthma, allergic rhinitis and seasonal rhinitis, but not currently active within 8 weeks prior to enrolment\n  * Absence of current or previous history of significant respiratory disease, other than COPD, asthma and allergic rhinitis\n* Permitted to have a positive skin test for atopy\n\nInclusion Criteria for non-smoking controls\n\n* Male or female sex\n* Age ≥ 40 years and ≤ 75 years at the time of signing the consent form\n* No history or clinical diagnosis of COPD\n* No significant smoking history, defined as:\n\n  * Less than 5 pack year cumulative smoking history\n  * Has not smoked or used e-cigarettes\u002Fvapes in the last 1 year\n* Controls spirometry criteria\n\n  * FEV1 of ≥80% predicted for age and height\n  * FEV1\u002FFVC ratio ≥0.7\n* Co-morbidity criteria:\n\n  * Permitted to have a past medical history of asthma, allergic rhinitis and seasonal rhinitis, but not currently active in the 8 weeks prior to enrolment\n  * Absence of current or previous history of significant respiratory disease, other than asthma and allergic rhinitis\n* Permitted to have a positive skin test for atopy.\n\nInclusion Criteria for smoking controls\n\n• Identical to non-smoking controls, with the exception of smoking history:\n\n* Cumulative smoking history of at least 20 pack years.\n* Permitted to currently use, or have history of use of, e-cigarettes\u002Fvapes\n\nExclusion Criteria:\n\n* Participants with other causes of chronic airflow limitation, including but not limited to:\n\n  * Bronchiectasis including cystic fibrosis\n  * Bronchiolitis obliterans\n  * Carcinoma of the bronchus\n  * Fibrosis such as tuberculosis (TB), idiopathic pulmonary fibrosis\n* Presence of any significant systemic disease, that in the opinion of the investigator would (a) make participation in the study unduly risky, or (b) significantly interfere with important outcomes being measured.\n\n  * For example, cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, haematological, psychiatric conditions.\n* Pregnant, planning to become pregnant, testing positive for pregnancy at the screening visit test, or nursing females during and within 30 days of treatment.\n* Treatment with oral, inhaled or nasal corticosteroids within 8 weeks prior to enrolment.\n* Treatment with antibiotics in the 8 weeks preceding enrolment.\n* Treatment with nasal medications, anti-leukotrienes, anti-histamine at the time of the study.\n* Presence (at screening) of serum rhinovirus-A16 neutralising antibodies in a titre \\>1:2.\n* Individuals with close contact to at risk patient group, including:\n\n  * Infants (less than 6 months);\n  * The extremely elderly or infirm;\n  * Pregnant and\u002For breastfeeding women;\n  * Patients with immunosuppression (e.g., human immunodeficiency virus (HIV), transplant recipients on anti-rejection medications, those undergoing chemo- or immuno-therapy).\n  * Other factors that in the opinion of the investigator are considered a risk.\n* Participation in other clinical research studies that, in the opinion of the investigator, would (a) make participation in the study unduly risky, or (b) significantly interfere with important outcomes being measured in this or other studies, or (c) present an unacceptable visit burden to the participant.",true,"75 Years",{"count":83,"type":22},50,"The goal of this study is to examine exacerbations of chronic obstructive pulmonary disease (COPD) caused by a common cold virus called rhinovirus, to identify new treatments. Exacerbations are flare-ups of respiratory symptoms which are a major cause of ill health in people with COPD, and are most commonly caused by viruses.\n\nThe main questions the study aims to answer are:\n\n* What processes in the body occur in response to rhinovirus infection, and do the differences between people with COPD and healthy volunteers explain why people with COPD develop more severe illness and exacerbations?\n* Can treatments be identified that target these processes to reduce the severity and frequency of exacerbations in people with COPD?\n\nThe study will compare eligible participants with COPD to healthy volunteers, and will involve intentionally infecting each participant with rhinovirus in a controlled environment. They will undergo baseline investigations prior to infection including a first bronchoscopy. Post-infection each participant will undergo a range of tests, including a second bronchoscopy, to compare how processes in the body, and especially the lungs, differ between people who do and do not have COPD.",[86,28,87],"COPD (Chronic Obstructive Pulmonary Disease)","Exacerbation of COPD",[89,90,91,92,93,94],"COPD","Chronic Obstructive Pulmonary Disease","Exacerbation","Multiomics","Rhinovirus","Viral challenge study","2026-04-13",{"date":97,"type":33},"2026-04-14",{"date":99,"type":33},"2025-10-08",{"date":101,"type":22},"2027-03-31",{"name":103,"class":104},"Imperial College London","OTHER",{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":111,"eligibilityCriteria":112,"healthyVolunteers":80,"sex":17,"minAge":113,"maxAge":114,"enrollmentInfo":115,"targetDuration":4,"studyType":23,"phases":117,"briefSummary":119,"conditions":120,"keywords":125,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":71},"100587639","a-rhinovirus-challenge-study-to-investigate-exacerbations-and-immune-responses-in-bronchiectasis-100587639","NCT06931002","A Rhinovirus Challenge Study to Investigate Exacerbations and Immune Responses in Bronchiectasis","Human Bronchiectasis Rhinovirus Challenge to Define Immunopathogenesis of Exacerbation","BARRIER","Inclusion Criteria:\n\n* For healthy volunteers:\n\n  1\\) Age 18 to 65 years.\n* For bronchiectasis study subjects:\n\n  1. Confirmed diagnosis of bronchiectasis aged 18-65 years with bronchiectasis severity index score of 0-8 .\n  2. For Pseudomonas colonised individuals, isolation of Pseudomonas aeruginosa in two or more cultures, at least 3 months apart in a 2-year period.\n\nExclusion Criteria:\n\n* For healthy volunteers and bronchiectasis study subjects:\n\n  1. Any medical co-morbidity impacting the study in the opinion of the medical team\n  2. Current smoking history within last 12 months or ex smoking history \\>5 pack years\n  3. Pre-existing serum neutralising antibodies to RV-A16 (strain to be used for challenge)\n  4. Close contact with infants or elderly individuals either at home or workplace\n  5. Pregnancy or breastfeeding\n* For bronchiectasis study subjects:\n\n  1\\) Individuals with bronchiectasis secondary to cystic fibrosis, primary immunodeficiency, primary ciliary dyskinesia and allergic bronchopulmonary aspergillosis 2) Individuals with other significant chronic lung disease diagnoses (eg. interstitial lung disease) which would impact the study in the opinion of the medical team 4) FEV1 \\\u003C 50% predicted 8) Recent antibiotics for exacerbations within the preceding 6 weeks and prophylactic antibiotics (azithromycin or nebulised antibiotics) within preceding 4 weeks 9) Corticosteroid use (inhaled, nasal or systemic) within preceding 4 weeks.","18 Years","65 Years",{"count":116,"type":22},54,[118],"NA","The goal of this study is to determine if viral infection with the common cold leads to an exacerbation in participants with bronchiectasis. The investigators will compare the participants with bronchiectasis to a group of healthy participants. The main questions it aims to answer are:\n\n* Does viral infection with the common cold lead to an exacerbation in bronchiectasis?\n* Does the immune response differ to that of a healthy participant?\n\nParticipants will attend for a screening visit to see if they are eligible. All participants who are eligible and have consented to take part will have baseline investigations done including blood tests and a bronchoscopy. They will be given a spray of a virus that causes the common cold into their nose. They will then be followed up over the next 6 weeks with some of the following procedures at each study visit; spirometry, nasosorption, nasal lavage, nasal brushing, blood test, sputum collection and a bronchoscopy. Participants will be asked to keep a daily record of their symptoms throughout the study.",[121,122,123,124,28],"Bronchiectasis Adult","Bronchiectasis With Acute Exacerbation","Bronchiectasis With Chronic Infection With Pseudomonas Aeruginosa","Viral Infection",[126,127,128],"bronchiectasis","rhinovirus","case control study","2025-07-04",{"date":131,"type":33},"2025-07-09",{"date":133,"type":33},"2024-07-24",{"date":135,"type":22},"2027-10-30",{"name":103,"class":104}]